Compass pathways stock forecast.

COMPASS Pathways (CMPS) Fundamentals Checker. Financial metrics are used to evaluate financial stability which helps analysts determine if COMPASS Pathways is undervalued compared to its fair value. A company's financial health can strongly influence the stock forecast.Still, if you're looking for an investment, COMPASS Pathways remains the most advanced company in psychedelics in terms of the maturity of its flagship pipeline program. Its psychedelic treatment ...COMPASS Pathways's market cap is currently ―. The company's EPS TTM is $-1.981; its P/E ratio is -2.86; COMPASS Pathways is scheduled to report earnings on March 4, 2024, and the estimated EPS forecast is $-0.34. See an overview of income statement, balance sheet, and cash flow financials. Dec 22. Sep 22.4 brokers have issued 1-year price targets for Atai Life Sciences' stock. Their ATAI share price targets range from $9.00 to $20.00. On average, they expect the company's stock price to reach $12.80 in the next twelve months. This suggests a possible upside of 1,063.6% from the stock's current price.COMPASS Pathways Stock Price, News & Analysis (NASDAQ:CMPS) $5.98 +0.05 (+0.84%) (As of 04:00 PM ET) Compare Today's Range $5.91 $6.56 50-Day Range …

BTIG analyst Robert Hazlett maintained a Buy rating on COMPASS Pathways (CMPS – Research Report) yesterday and set a price target of $47.0... BTIG analyst Robert Hazlett maintained a Buy rating on COMPASS Pathways (CMPS – Research Rep...7 de jul. de 2023 ... COMPASS Pathways PLC (CMPS) stock is trading at $10.70 as of 11:57 AM on Friday, Jul 7, a gain of $1.36, or 14.56% from the previous closing ...

COMPASS Pathways PLC ADR analyst ratings, historical stock prices, earnings estimates & actuals. CMPS updated stock price target summary.Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange requirements. Close Trending Tickers bar

For Compass Pathways, ( CMPS 2.01%) whose COMP360 program aims to address treatment-resistant depression (TRD) with a combination of psilocybin and clinician-led psychological support, that's ...Zacks forecast a loss of 55 cents per share. The company had zero revenue, as its main product, COMP360, is still in trials. ... Compass Pathways stock is in an IPO base with a 47.39 buy point.Compass Pathways initiates UK component of global phase 3 study of psilocybin treatment in treatment-resistant depression, and launches new research center. Read more. Compass is a biotechnology company dedicated to accelerating patient access and experience to evidence-based innovation in mental health care.markets.businessinsider.com - August 7 at 4:42 PM. HC Wainwright Reiterates "Buy" Rating for COMPASS Pathways (NASDAQ:CMPS) marketbeat.com - August 4 at 2:37 PM. Compass Pathways Plc (CMPS) Q2 2023 Earnings Call Transcript. finance.yahoo.com - August 4 at 4:00 AM. COMPASS Pathways Q2 2023: $148.2M Cash Position, Steady …

COMPASS Pathways EBIT Forecast for 2023 - 2025 - 2030. In the last year, COMPASS Pathways's EBIT has grown from $-47.15M to $-73.57M – a 56.03% increase. For the …

Summary. BiotechValley Insights is initiating coverage of COMPASS Pathways with a "Bearish" rating at a $13 PT. CMPS has filed an IPO with an initial valuation of US$544M; since then, the stock ...

Compass Pathways Plc ADR (CMPS) shares have gone down -22.59% during the last six months, with a year-to-date growth rate less than the industry average at -3.70% against 5.90. Yet analysts are ramping up their growth forecast for the fiscal year 2023. Revenue is predicted to grow 64.40% this quarter and then jump 7.00% in the …WebStock analysis for Compass Pathways Plc (CMPS:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.The 10 analysts offering 12-month price forecasts for Compass Pathways PLC have a median target of 33.00, with a high estimate of 120.00 and a low estimate of 19.00. This indicates a potential increase of 254.08% from the last recorded price of 9.32. The consensus among 11 polled investment analysts is to buy stock in Compass Pathways PLC.COMPASS Pathways (NASDAQ: CMPS) has seen its earnings outlook for FY2023 revised by Cantor Fitzgerald. The equities researchers at Cantor Fitzgerald have raised their EPS estimates, predicting that the company will now earn ($2.08) per share for the year, up from their previous forecast of ($2.24).Dec 1, 2023 · COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.

The upgrade of COMPASS Pathways PLC Sponsored ADR to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move ...Nov 29, 2023 · About CMPS. COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. Discover COMPASS Pathways' earnings and revenue growth rates, forecasts, and the latest analyst predictions while comparing them to its industry peers.9 พ.ย. 2564 ... Compass Pathways stock plunged, despite the company reporting that a strong dose of a psilocybin-based drug helped reduce depression.That's true for all of the existing public psychedelic biotechs engaged in drug development, including such industry leaders as Compass Pathways (CMPS-2.26%) and Atai Life Sciences (ATAI-1.51% ...Nov 13, 2023 · Future criteria checks 0/6. COMPASS Pathways's earnings are forecast to decline at 2.7% per annum while its annual revenue is expected to grow at 82.4% per year. EPS is expected to grow by 6.1% per annum. Return on equity is forecast to be -82.5% in 3 years.

It may have a tough pill to swallow, but I'm still optimistic about psilocybin in general, and especially Cybin....CMPS At the time of publication, Tim Collins was long CYBN. Look how quickly we got bulled up. Let's check sentiment, the...COMPASS Pathways plc (COMPASS) operates as a mental health care company. The company engages in the development of a new model of psilocybin therapy, in which its investigational COMP360 psilocybin is administered in conjunction with psychological support. Its initial focus is on treatment-resistant depression (TRD), a subset of major ...

COMPASS Pathways EBIT Forecast for 2023 - 2025 - 2030. In the last year, COMPASS Pathways's EBIT has grown from $-47.15M to $-73.57M – a 56.03% increase. For the …Psychedelics biotech giant COMPASS Pathways (NASDAQ: CMPS) has entered into a securities purchase agreement for an initial $125 million and potential additional of $160 million, with a select ...Compass shares are also dragging in late 2023, down 26.3% on a year-to-date basis. The U.K.-based biotech, which specializes in psilocybin research for treating depression, recently landed $285 ...For COMPASS Pathways plc stock forecast for 2023, 2 predictions are offered for each month of 2023 with average COMPASS Pathways plc stock forecast of $5.33, a high forecast of $5.36, and a low forecast of $5.3. The average COMPASS Pathways plc stock forecast 2023 represents a 0.88% increase from the last price of $5.28499984741211.COMPASS Pathways - Overview (February Company Presentation) Recent Events: Compass posted fourth quarter results one week ago. The company posted a net loss of $25.7 million for the quarter and ...On Nov 02, 2023, Compass Pathways ( NASDAQ: CMPS) reported Q3 2023 earnings per share (EPS) of -$0.67, up 55.81% year over year. Total Compass Pathways earnings for the quarter were -$33.39 million. In the same quarter last year, Compass Pathways 's earnings per share (EPS) was -$0.43. If you're new to stock investing, here's how to buy …Last Friday, U.K.-based Compass Pathways (NASDAQ: CMPS) became the first psychedelic medicine company to go public on a major U.S. exchange. The drugmaker's shares promptly rose by an eye-catching ...Still, if you're looking for an investment, COMPASS Pathways remains the most advanced company in psychedelics in terms of the maturity of its flagship pipeline program. Its psychedelic treatment ...

COMPASS Pathways plc operates as a mental health care company primarily in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.

Nov 13, 2021 · A buy now? Luckily, Compass Pathways stock doesn't have a rousing success for COMP360 already baked into its price. The company's market cap of $1.4 billion at the moment isn't terribly high for a ...

Discover historical prices for CMPS stock on Yahoo Finance. View daily, weekly or monthly format back to when COMPASS Pathways plc stock was issued.16 de ago. de 2023 ... The psychedelics biotech firm is set to receive $125 million selling stocks upfront, with a potential addition of $160 million from ...See COMPASS Pathways plc (CMPS) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades.According to 5 stock analysts, the average 12-month stock price forecast for CMPS stock stock is $49.6, which predicts an increase of 668.99%. The lowest target is $19 and the highest is $120. On average, analysts rate CMPS stock stock as a strong buy.According to COMPASS Pathways's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.54468. At the end of 2022 ...On average, Wall Street analysts predict. that Compass Pathways's share price could reach $57.25 by Aug 22, 2024. The average Compass Pathways stock price prediction forecasts a potential upside of 857.36% from the current CMPS share price of $5.98. UK-based COMPASS Pathways recently published data from its Phase IIb trials, with COMP360 psilocybin therapy for treatment-resistant depression. This follows the release of the design for the company’s pivotal Phase III trials, the first-ever Phase III psilocybin therapy trial and the final studies prior to market approval. With the treatment’s …Shares of psychedelics-inspired medicine developer COMPASS Pathways (NASDAQ: CMPS) jumped more than 5% on Monday, ... CMPS Stock Price Forecast. Long-term, we love COMPASS Pathways.Web

Nov 27, 2023 · The Compass Pathways PLC stock price fell by -6.05% on the last day (Monday, 27th Nov 2023) from $6.45 to $6.06. During the last trading day the stock fluctuated 13.20% from a day low at $5.80 to a day high of $6.56. The price has risen in 6 of the last 10 days and is up by 14.99% over the past 2 weeks. Volume has increased on the last day by ... Despite the potential of EVgo, Inc. (EVGO), Amyris, Inc. (AMRS), and COMPASS Pathways plc (CMPS) springing a surprise during the earnings season, their less-than-ideal fundamentals deem it wise to avoid placing any long-term bets on these heavily shorted stocks.In 2021, easy money, unprecedented hype created by retail …Discover COMPASS Pathways' earnings and revenue growth rates, forecasts, and the latest analyst predictions while comparing them to its industry peers.Bid Price and Ask Price. The bid & ask refers to the price that an investor is willing to buy or sell a stock. The bid is the highest amount that a buyer is ...Instagram:https://instagram. spacex valuation 2023best options trading serviceotcmkts chdrfman u shares price Compass Pathways (CMPS) buy sell technical analysis & forecast predictions with share price targets for today short term. Compass Pathways (CMPS) Share trades in NASDAQ in NASDAQ stock exchange. Important intraday levels for the stock on upside are: 10 and 11 and 12 If the stock moves up, then it will find resistance near these levels. best private health insurance for type 1 diabetesbest futures brokers 9 พ.ย. 2564 ... Compass Pathways CEO on mushroom-based therapy for depression ... Global Business and Financial News, Stock Quotes, and Market Data and Analysis.View the latest COMPASS Pathways PLC ADR (CMPS) stock price, news, historical charts, analyst ratings and financial information from WSJ. investing simulators Real-time share price updates and latest news for Compass Pathways ADR (NASDAQ:CMPS). Compare across sectors, industries & regions.Math Over Myth: Spotlight on Psychedelic Stocks ATAI & COMPASS. by Craig Schlesinger on September 9, 2022. If you want to invest in psychedelic stocks, ignore the hype and look at the technicals. …